Screener
Halozyme Therapeutics HALO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Inventories | 45,711 | (15,126) |
| Prepaid expenses and other assets | (50,256) | (41,063) |
| Accounts payable and accrued expenses | (47,833) | (20,474) |
| Net cash provided by operating activities | 420,969 | 253,932 |
| Investing activities | ||
| Purchases of marketable securities | (120,605) | (242,399) |
| Proceeds from sales and maturities of marketable securities | 62,269 | 239,278 |
| Proceeds from working capital adjustments on acquisition | 710 | — |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's operating cash flow?
- Halozyme Therapeutics (HALO) reported operating cash flow of $240.89M in Q2 2026.
- How has Halozyme Therapeutics's operating cash flow changed year-over-year?
- Halozyme Therapeutics's operating cash flow increased by 141.6% year-over-year, from $99.71M to $240.89M.
- What is the long-term trend for Halozyme Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's operating cash flow has grown at a 21.5% compound annual growth rate (CAGR), from $299.44M to $651.56M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Halozyme Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude